Welcome to our Clinical Studies section
Clinical studies involving healthy volunteers and patients play a vital role in the development of new drugs. These studies are conducted to ensure that all investigational drugs are safe and effective. Over recent years, along with drug discovery, drug development and clinical studies have benefitted from scientific and technological advancements as well as a greater understanding of the needs clinical study participants have.
At UCB we’ve moved away from seeing patients as just patients. By really listening and engaging with them as partners we are striving for greater understanding of their needs or ways to improve our clinical studies. To improve and accelerate development, we will keep patients’ needs front and center, leverage new technologies, and adaptive clinical study design to improve the patient experience.
Diversification of clinical trials is critical, and UCB is working to increase representation and inclusion of underrepresented patient populations through digital and data-driven approaches as well as connecting directly to patient communities. We are committed to working toward a clinical trials infrastructure that addresses health disparities and closes the gap in clinical trial diversity to better reflect the intended treatment population. We continue our work to identify best practices around key drivers such as scientific rigor, informing innovation, and addressing health inequities in clinical trials now and into the future.
Current clinical studies at a glance
Find out more about a selection of studies
A Phase 3, Randomized, Double-Blind, Placebo-controlled, Fixed-dose, Multicenter Study to Examine the Efficacy and Safety of ZX008 in Subjects with CDKL5 Deficiency Disorder Followed by an Open-Label Extension
A Phase I/IIA, Randomized, Placebo-Controlled, Single-Ascending Dose (Part A, Participant- and Investigator-Blind) and Repeated-Dose (Part B, Participant-, Investigator-, and Sponsor-Blind) Study to Investigate the Safety, Pharmacokinetics, and Efficacy of UCB9741 in Healthy Study Participants (Part A) and in Study Participants With Moderate-to-Severe Atopic Dermatitis (Part B)
A Randomized, Dose-Finding and Confirmatory, Double-Blind, Placebo-Controlled, Parallel-Group Multicenter Study With a 2 Stage Adaptive Design and Randomized Withdrawal to Evaluate the Efficacy, Safety, and Tolerability of Brivaracetam as Monotherapy in Patients 2 to 25 Years of Age With Childhood Absence Epilepsy or Juvenile Absence Epilepsy
A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase 3, Pivotal Study With an Open-Label Extension Period to Evaluate the Efficacy and Safety of Rozanolixizumab in Adult Participants With Myelin Oligodendrocyte Glycoprotein (MOG) Antibody-Associated Disease (MOG-AD)
A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase 2 Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Rozanolixizumab in Adult Study Participants With Leucine-Rich Glioma Inactivated 1 Autoimmune Encephalitis
A Double-Blind, Randomized, Placebo-Controlled, Multicenter, Outpatient, Parallel-Group Study to Assess the Efficacy and Safety of Staccato Alprazolam in Study Participants 12 Years of Age and Older With Stereotypical Prolonged Seizures
An Open-Label, Multicenter, Outpatient Extension Study to Evaluate the Safety and Tolerability of Staccato Alprazolam in Study Participants 12 Years of Age and Older With Stereotypical Prolonged Seizures
Multicenter, Randomized, Parallel-Group, Double-Blind, Placebo-Controlled (12-17 Years) Including a Single Open-Label Arm (6-11 Years) Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Certolizumab Pegol (CZP) in Pediatric Study Participants With Moderate to Severe Chronic Plaque Psoriasis (PSO)
Discover more about our clinical studies
+1 866 709 8444
+4021 300 19 07
+41 58 822 3180
People don't see my disease and how it threatents my independence,
and those same people don't realise that they, too, could be at risk.
Lut, living with osteoporosis